Nitric oxide: Novel therapy for osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 3025-3044

  Wimalawansa, Sunil J ^a  

^a Regional Osteoporosis Center   (United States)

Author keywords

Glyceryl trinitrate; Hormone replacement therapy; Menopause; Nitric oxide donors; Nitric oxide synthase inhibitors; Nitroglycerin; Osteopoenia; Osteoporosis; RANK; Vascular system

Indexed keywords

ALENDRONIC ACID; AMINOGUANIDINE; ARGININE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; GLYCERYL TRINITRATE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE MONONITRATE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE DONOR; PLACEBO; PROGESTERONE; RALOXIFENE; TESTOSTERONE; VITAMIN D;

AUTOCRINE EFFECT; BONE DENSITY; BONE TURNOVER; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ESTROGEN THERAPY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; PARACRINE SIGNALING; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ANIMALS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; NITRIC OXIDE; OSTEOPOROSIS; STRESS, MECHANICAL;

EID: 57549089218     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802197162     Document Type: Review

References (108)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43(2):109-42
2. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84(24):9265-9
3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327(6122):524-6
4. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994;120(3):227-37
5. Wimalawansa SJ. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann NY Acad Sci 2007;1117:283-97
6. Margolis RN, Wimalawansa SJ. Novel targets and therapeutics for bone loss. Ann NY Acad Sci 2006;1068:402-9
7. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329(27):2002-12
8. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298(Pt 2):249-58
9. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Ann Rev Physiol 1995;57:737-69
10. Wimalawansa SJ. Nitric oxide: new evidence for novel therapeutic indications. Expert Opin Pharmacother 2008;9(11):1935-54
11. Angus JA, Cocks TM. Endothelium-derived relaxing factor. Pharmacol Ther 1989;41(1-2):303-52
12. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218(3):739-49
13. Wimalawansa SJ. Skeletal effects of nitric oxide: novel agent for osteoporosis. In: Billizikiean JMT, editor, Principles of Bone Biology. 3rd ed. NY: Academic Press; 2008;59:1275-311
14. Stacey E, Korkia P, Hukkanen MV, et al. Decreased nitric oxide levels and bone turnover in amenorrheic athletes with spinal osteopenia. J Clin Endocrinol Metab 1998;83(9):3056-61
15. Rosselli M, Imthurn B, Keller PJ, et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension 1995;25(4 Pt 2):848-53
16. Cicinelli E, Ignarro LJ, Lograno M, et al. Circulating levels of nitric oxide in fertile women in relation to the menstrual cycle. Fertil Steril 1996;66(6):1036-8
17. Cicinelli E, Ignarro LJ, Schonauer LM, et al. Effects of short-term transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 1998;69(1):58-61
18. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996;18(4):301-4
19. WHI. Risks and benefits of estrogen plus progentin in healthy postmenopausal women. JAMA 2002;288:321-33
20. Wimalawansa SJ, Chapa MT, Yallampalli C, et al. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone 1997;21(3):275-80
21. Consensus Development Conference. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95
22. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, 2000 March 7 - 29: highlights of the conference. South Med J 2001;94(6):569-73
23. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95
24. Wimalawansa SJ. Calcitonin gene-related peptide: isolation, purification, and characterization of receptors. PhD Thesis, University of London; 1988
25. Sunyer T, Rothe L, Jiang X, et al. Proinflammatory agents, IL-8 and IL-10, upregulate inducible nitric oxide synthase expression and nitric oxide production in avian osteoclast-like cells. J Cell Biochem 1996;60(4):469-83
26. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11(2):76-81
27. van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001;103(3):255-61
28. Kerwin JF Jr, Lancaster JR Jr, Feldman PL. Nitric oxide: a new paradigm for second messengers. J Med Chem 1995;38(22):4343-62
29. Wimalawansa SJ. Rastoration of ovariectomy-induced osteopenia by nitroglycerin. Calcif Tissue Int 2000;66(1):56-60
30. Bonnelye E, Aubin JE. Estrogen receptor-related receptor alpha: a mediator of estrogen response in bone. J Clin Endocrinol Metab 2005;90(5):3115-21
31. Wimalawansa SJ. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 2000;15(11):2240-4
32. Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 1989;125(2):825-33
33. Qu Q, Perala-Heape M, Kapanen A, et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 1998;22(3):201-9
34. Ernst M, Schmid C, Froesch ER. Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci USA 1988;85(7):2307-10
35. Scheven BA, Damen CA, Hamilton NJ, et al. Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun 1992;186(1):54-60
36. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241(4861):84-6
37. Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988;241(4861):81-4
38. Tanko-Yamamoto T, Rodan GA. Direct effects of 17 betaestradiol on trabecular bone in overiectomized rats. Proc Natl Acad Sci USA 1990;88:2172-6
39. Chow J, Tobias JH, Colston KW, Chambers TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 1992;89(1):74-8
40. Samuels A, Perry MJ, Tobias JH. High-dose estrogen induces de novo medullary bone formation in female mice. J Bone Miner Res 1999;14(2):178-86
41. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995;214(3):847-55
42. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91(11):5212-6
43. Armour KE, Ralston SH. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology 1998;139(2):799-802
44. O'Shaughnessy MC, Polak JM, Afzal F, et al. Nitric oxide mediates 17beta-estradiol-stimulated human and rodent osteoblast proliferation and differentiation. Biochem Biophys Res Commun 2000;277(3):604-10
45. Riancho JA, Salas E, Zarrabeitia MT, et al. Expression and functional role of nitric oxide synthase in osteoblast-like cells. J Bone Miner Res 1995;10(3):439-46
46. Chae HJ, Park RK, Chung HT, et al. Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol 1997;49(9):897-902
47. Wimalawansa DR, Wimalawansa SM, Yallampalli C, Wimalawansa SJ. Enhancement of bone mineral density with the combination of nitric oxide donors and bisphosphonates therapy. Calcif Tissue Int 2008; In publication
48. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 2001;7(8):715-36
49. Kawase T, Howard GA, Roos BA, Burns DM. Nitric oxide stimulates mineralization in osteoblastic cell cultures. J Bone Miner Res 1993;8:S372
50. Armour KE, Armour KJ, Gallagher ME, et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001;142(2):760-6
51. Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE. Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest 1994;93(4):1465-72
52. Brandi ML, Hukkanen M, Umeda T, et al. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA 1995;92(7):2954-8
53. Silverton SF, Adebanjo OA, Moonga BS, et al. Direct microsensor measurement of nitric oxide production by the osteoclast. Biochem Biophys Res Commun 1999;259(1):73-7
54. MacIntyre I, Zaidi M, Alam AS, et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci USA 1991;88(7):2936-40
55. Ralston SH, Todd D, Helfrich M, et al. Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinology 1994;135(1):330-6
56. Hukkanen M, Hughes FJ, Buttery LD, et al. Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat, and human osteoblast-like cells and its functional role in osteoblast metabolic activity. Endocrinology 1995;136(12):5445-53
57. Armour KE, Van'T Hoff RJ, Grabowski PS, et al. Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res 1999;14(12):2137-42
58. Armour KJ, van't Hof RJ, Armour KE, et al. Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). Arthritis Rheum 2001;44(9):2185-92
59. Kasten TP, Collin-Osdoby P, Patel N, et al. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci USA 1994;91(9):3569-73
60. Fini M, Torricelli P, Giavaresi G, et al. Effect of L-lysine and L-arginine on primary osteoblast cultures from normal and osteopenic rats. Biomed Pharmacother 2001;55(4):213-20
61. Broulik PD, Haluzik M, Skrha J. The influence of nitric oxide synthase inhibitor L-NAME on bones of male rats with streptozotocin-induced diabetes. Physiol Res 2003;52(6):729-34
62. Lee SK, Huang H, Lee SW, et al. Involvement of iNOS-dependent NO production in the stimulation of osteoclast survival by TNF-alpha. Exp Cell Res 2004;298(2):359-68
63. Punjabi CJ, Laskin DL, Heck DE, Laskin JD. Production of nitric oxide by murine bone marrow cells. Inverse correlation with cellular proliferation. J Immunol 1992;149(6):2179-84
64. Pitsillides AA, Rawlinson SC, Suswillo RF, et al. Mechanical strain-induced NO production by bone cells: a possible role in adaptive bone (re)modeling? FASEB J 1995;9(15):1614-22
65. Sterck JG, Klein-Nulend J, Lips P, Burger EH. Response of normal and osteoporotic human bone cells to mechanical stress in vitro. Am J Physiol 1998;274(6 Pt 1):E1113-20
66. Burger EH, Klein-Nulen J. Responses of bone cells to biomechanical forces in vitro. Adv Dent Res 1999;13:93-8
67. Turner CH, Takano Y, Owan I, Murrell GA. Nitric oxide inhibitor L-NAME suppresses mechanically induced bone formation in rats. Am J Physiol 1996;270(4 Pt 1):E634-9
68. Zaman G, Pitsillides AA, Rawlinson SC, et al. Mechanical strain stimulates nitric oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J Bone Miner Res 1999;14(7):1123-31
69. Dong SS, Williams JP, Jordan SE, et al. Nitric oxide regulation of cGMP production in osteoclasts. J Cell Biochem 1999;73(4):478-87
70. Lin SK, Kok SH, Kuo MY, et al. Nitric oxide promotes infectious bone resorption by enhancing cytokine-stimulated interstitial collagenase synthesis in osteoblasts. J Bone Miner Res 2003;18(1):39-46
71. Aguirre J, Buttery L, O'Shaughnessy M, et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol 2001;158(1):247-57
72. Armour KJ, Armour KE, van't Hof RJ, et al. Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 2001;44(12):2790-6
73. Turner CH, Owan I, Jacob DS, et al. Effects of nitric oxide synthase inhibitors on bone formation in rats. Bone 1997;21(6):487-90
74. Fox SW, Chambers TJ, Chow JW. Nitric oxide is an early mediator of the increase in bone formation by mechanical stimulation. Am J Physiol 1996;270(6 Pt 1):E955-60
75. Wimalawansa SJ, Simmons DJ. Prevention of corticosteroid-induced bone loss with alendronate. Proc Soc Exp Biol Med 1998;217(2):162-7
76. Thompson LP, Pinkas G, Weiner CP. Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation 2000;102(4):445-51
77. Hernandez I, Delgado JL, Diaz J, et al. 17beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2000;279(5):R1599-605
78. Guetta V, Quyyumi AA, Prasad A, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96(9):2795-801
79. Arnal JF, Clamens S, Pechet C, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci USA 1996;93(9):4108-13
80. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6(9):1004-10
81. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85(8):2966-9
82. Aguirre JI, Igal SU, Larsen A, et al. Endothelial nitric oxide synthase expression decreased in the growth plate but increases in the metaphyses of bones from lactating rats in association with reduced endochondral growth and increased resorption and osteoid deposition. 2003
83. Wimalawansa S, Chapa T, Fang L, et al. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. J Bone Miner Res 2000;15(6):1119-25
84. Wimalawansa SJ. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. J Clin Densitom 2000;3(2):187-201
85. Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988;123(5):2571-7
86. Wimalawansa SM, Shankar VS, Simmins DJ, Wimalawansa SJ. The mechanism of bone resorption by cyclosporin: involvement of the NO-cGMP pathway. J Musculoskelet Neuronal Interact 2000;1(2):141-3
87. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999;138(3 Pt 1):577-85
88. Munzel T. Does nitroglycerin therapy hit the endothelium? J Am Coll Cardiol 2001;38(4):1102-5
89. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002;99(12):8306-11
90. Orsi A, Beltran B, Clementi E, et al. Continuous exposure to high concentrations of nitric oxide leads to persistent inhibition of oxygen consumption by J774 cells as well as extraction of oxygen by the extracellular medium. Biochem J 2000;346(Pt 2):407-12
91. Beltran B, Orsi A, Clementi E, Moncada S. Oxidative stress and S-nitrosylation of proteins in cells. Br J Pharmacol 2000;129(5):953-60
92. Collin-Osdoby P. Role of vascular endothelial cells in bone biology. J Cell Biochem 1994;55(3):304-9
93. Wimalawansa SJ, Grimes J, Hoover D, Wilson A. Use of nitric oxide donor, nitroglycerin as a therapeutic agent for osteoporosis: NOVEL 1. Am Med J 2008; Submitted
94. Rosselli M, Imthurm B, Macas E, et al. Circulating nitrite/nitrate levels increase with follicular development: indirect evidence for estradiol mediated NO release. Biochem Biophys Res Commun 1994;202(3):1543-52
95. Tas N, Aricioglu A, Erbas D, Ozcan S. The effect of calcitonin treatment on plasma nitric oxide levels in post-menopausal osteoporotic patients. Cell Biochem Funct 2002;20(2):103-5
96. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104(3):219-26
97. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998;13(11):1755-9
98. Visser JJ, Hoekman K. Arginine supplementation in the prevention and treatment of osteoporosis. Med Hypotheses 1994;43(5):339-42
99. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99(1):36-42
100. The NOVEL Study. Nitroglycerin as an Option: Value in Early Bone Loss. Available from: http://www2.umdni.edu/novelweb
101. Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women. Available from: http://clinicaltrials.gov/show/NCT00043719
102. Wimalawansa SJ, Grimes J, Chen F, et al. Osteoporosis in postmenapausal women: development of a cost-effective novel therapy NOVEL clinical study. Targeting bone remodelling for the treatment of osteoporosis [abstract 37]. ASBMR/NIH Symposium; December 2007; Washington DC, USA
103. Wimalawansa SJ, Grimes JP, Wilson A, Hoover DR. The nitroglycerin as an option value in early bone loss (NOVEL): clinical trial on prevention of postmenopausal bone less. JBMR (In press)
104. Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 2006;21(11):1811-7
105. Jamal SA. Cummings SR, Hawker GA. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res 2004;19:1512-17
106. Jamal SA, Goltzman D, Hanley DA, et al. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2008 Sep 18
107. Nabhan AF, Rabie NH Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. Int J Gynaecol Obstet 2008 Sep 20.
108. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996;17(5):533-85